Compare AN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AN | SRRK |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.8B |
| IPO Year | 1995 | 2018 |
| Metric | AN | SRRK |
|---|---|---|
| Price | $209.26 | $52.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $244.33 | $56.17 |
| AVG Volume (30 Days) | 410.2K | ★ 1.0M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.71 | N/A |
| EPS | ★ 11.26 | N/A |
| Revenue | ★ $27,631,400,000.00 | N/A |
| Revenue This Year | $4.32 | N/A |
| Revenue Next Year | $2.89 | $534.24 |
| P/E Ratio | $18.49 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $176.62 | $27.07 |
| 52 Week High | $235.81 | $58.49 |
| Indicator | AN | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 54.87 |
| Support Level | $200.58 | $44.26 |
| Resistance Level | $218.10 | $58.49 |
| Average True Range (ATR) | 8.43 | 2.32 |
| MACD | -1.38 | 0.49 |
| Stochastic Oscillator | 33.90 | 73.35 |
AutoNation is the second-largest automotive dealer in the United States, with 2025 revenue of $27.6 billion and over 245 dealerships, plus 52 collision centers. The firm also has 24 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors across 20 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) divested its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which proved to be a smart move.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.